The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L04 | Immunosuppressants | |
3
|
L04A | Immunosuppressants | |
4
|
L04AH | Mammalian target of rapamycin (mTOR) kinase inhibitors |
| Code | Title | |
|---|---|---|
| L04AH01 | Sirolimus | |
| L04AH02 | Everolimus |
| Active Ingredient |
|---|
|
Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers. |
|
Sirolimus inhibits T-cell activation induced by most stimuli, by blocking calcium-dependent and calcium-independent intracellular signal transduction. Studies demonstrated that its effects are mediated by a mechanism that is different from that of ciclosporin, tacrolimus, and other immunosuppressive agents. |
| Document | Type | Information Source | |
|---|---|---|---|
| HYFTOR Gel | MPI, EU: SmPC | European Medicines Agency (EU) | |
| RAPAMUNE Coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| VOTUBIA Dispersible tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| VOTUBIA Tablet | MPI, EU: SmPC | European Medicines Agency (EU) |